{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"To evaluate safety and tolerability of fenofibrate therapy in patients with multiple myeloma.","groups":[{"description":"Fenofibrate orally daily for each 28 day cycle, per study protocol.\n\nFenofibrate: Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \\< 50 mL/min will receive a reduced dose of 54 mg orally daily.","id":"OG000","title":"Fenofibrate Therapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 8 months","title":"Number of Subjects Experiencing Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}